about
A design for phase I trials in completely or partially ordered groups.Performance of toxicity probability interval based designs in contrast to the continual reassessment method.Dimension of model parameter space and operating characteristics in adaptive dose-finding studies.Practical designs for Phase I combination studies in oncologyA comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.Phase I design for completely or partially ordered treatment schedules.Phase I/II adaptive design for drug combination oncology trialspocrm: an R-package for phase I trials of combinations of agents.Specifications of a continual reassessment method design for phase I trials of combined drugs.Using the time-to-event continual reassessment method in the presence of partial ordersObtaining the optimal dose in alcohol dependence studies.Dose-finding design for multi-drug combinations.BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic orderingInnovations for phase I dose-finding designs in pediatric oncology clinical trials.Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses.Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.Adaptive designs for dual-agent phase I dose-escalation studies.Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.A product of independent beta probabilities dose escalation design for dual-agent phase I trials.Effect of design specifications in dose-finding trials for combination therapies in oncology.A two-dimensional biased coin design for dual-agent dose-finding trials.Design considerations for dose-expansion cohorts in phase I trialsA practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.Recent developments in the implementation of novel designs for early-phase combination studies.Isotonic designs for phase I trials in partially ordered groups.Escalation with overdose control for phase I drug-combination trials.Phase I trial design for drug combinations with Bayesian model averaging.Some statistical considerations in the clinical development of cancer immunotherapies.A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.Competing designs for drug combination in phase I dose-finding clinical trials.
P2860
Q30252706-1975F087-A009-4AAD-B877-172C33C92F18Q30276332-F3134875-963F-4DEE-9770-5E79B64A0B02Q30276967-783BE807-0D63-4F10-857C-F5923D4B4FD2Q30278669-A0FC120C-EC1A-4AC6-AF34-4D34DF608BF5Q30299951-705439F4-C776-4651-B029-72227C679C92Q30301141-80400475-8EC4-4AAE-B0DD-34BFD25CEA50Q30371414-8C3928D1-D326-448C-870A-AD2A39504BEEQ30407970-80FB8B0B-3683-42F7-B2A3-40A27269FBCDQ30409168-1D68FA7D-AA6F-46D3-8912-2E3C3346A770Q30410385-B498E7EC-F30C-4FF7-B72E-98BD2C074DF5Q30412231-3F751721-72A8-4B70-9AC0-D6DFFB8481E5Q30422422-5D10ADFB-05A4-420C-B22D-D3801556C0C9Q30423823-D2DDED39-6E09-4B01-A5CD-C8BDEC393873Q30424392-AA590694-2B65-4E7E-B9F9-72AEE7862AA6Q30795111-2566CDA6-7287-4508-AE67-9D6B3DC83938Q34001009-7B07CC14-5DB8-479A-9ECA-C33F531DD1CDQ34143140-0EAF1032-19AA-466D-9620-86CAA86D99A2Q35175343-BCC2B388-F041-44DA-9707-C5A0779F072FQ36757843-1CE13692-03F0-4F3E-8763-EC4C733ECBC3Q37099409-1C2B3C74-9B4F-4C3C-B957-25CDCB9F3CFAQ37129865-26CE9511-6B8D-4EE6-9F32-8896B72ABF44Q37478123-2ECADCB9-143C-4E18-8C43-E1D1A08E5F2BQ37552881-12E48C6C-3822-404B-BD1F-5E93666DC200Q38090897-5DDFE5FF-CFD9-4C3E-81ED-A7BDD091F3FBQ38735952-6D60783E-482B-4664-9A50-D494A73DA065Q39125629-02FECC22-0103-4ED1-8AA1-410750DB12FFQ39958094-941A600B-FC49-4406-B772-28B1330A1E6AQ40616106-AE65B3A7-37F5-419B-BCF3-C6B2E0117598Q40749503-B4A96F5B-9DF0-44F5-8E6F-314E967F753AQ41895594-F4AA50E0-6955-458D-9304-98A30DD3C227Q44494502-00B56164-EAAB-4B8C-8015-086AD7D768B3Q45009575-CB45BAE2-B5C2-4A29-BB15-13C527D49C1DQ45064728-CCB83F58-AE94-4A6C-B9C4-436153AB6B32Q45834856-297758BA-4CE4-4113-9024-0E3ACCA82C5DQ47751410-F8409C23-EDC6-4616-8975-5E239B0BA62AQ48369935-37082F16-56FE-416E-8292-CC6F34E52A82Q49233311-B6001FE1-62CC-43AA-97C7-0CE63DDD42A8Q51016744-67AD66F3-64AD-4800-A69F-2A733EFA3290Q51086024-2D975BDB-DDDD-462C-AAF1-C25367B9F562Q51119546-F69C881C-D53E-48A7-BE7E-C7EF083FA2DA
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Continual reassessment method for partial ordering.
@ast
Continual reassessment method for partial ordering.
@en
type
label
Continual reassessment method for partial ordering.
@ast
Continual reassessment method for partial ordering.
@en
prefLabel
Continual reassessment method for partial ordering.
@ast
Continual reassessment method for partial ordering.
@en
P2093
P2860
P1433
P1476
Continual reassessment method for partial ordering.
@en
P2093
John O'Quigley
Mark R Conaway
Nolan A Wages
P2860
P304
P356
10.1111/J.1541-0420.2011.01560.X
P407
P577
2011-03-01T00:00:00Z